A novel biomarker for glioma: a powerful new prognostic tool?

Written by Hannah Makin

A recent study published in the journal EBioMedicine has demonstrated that a potential biomarker, SHOX2, may help researchers to predict the survival outcome of patients with diffuse glioma brain tumors. These findings could aid the development of new therapeutic targets and allow clinicians to determine more effectively the best treatment plan for individual patients. Predicating the survival of patients with lower-grade gliomas (LGGs), grades II and III, has so far proven difficult due to their highly variable clinical course. This variability has spurred many studies to find a potential prognostic biomarker that could permit effective prediction of survival outcome. In...

To view the full article, please register now for access

It's completely free